Abstract
In March 2021, Novartis announced a positive result for both primary endpoints of the randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu-PSMA-617 RLT and the best standard of care improved both overall and radiographic progression-free survival when compared with
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Paper Title
Journal
Date
